ArticleClinical and translational gastroenterology2025
Does Prior Bariatric Surgery Predispose to Acetaminophen-Related Acute Liver Failure?
Article in Clinical and translational gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionPrior small studies have suggested that patients with prior metabolic and bariatric surgery (MBS) may have increased susceptibility to acetaminophen (APAP)-related acute liver failure/acute liver injury (ALF/ALI). The aim of this study was to compare the presentation, etiology, and outcome of adult ALI/ALF patients who were enrolled in a prospective registry study with prior bariatric surgery to those without.
methodsAmong 3,364 ALF/ALI patients in the Acute Liver Failure Study Group registry enrolled between January 1998 and August 2019, 85 (2.3%) reported prior MBS. On review, 6 cases were deemed not ALF and excluded from the analysis.
resultsAmong the 79 MBS ALF/ALI patients, 95% were female and 86% were White. Etiology included APAP-related ALF/ALI in 78.5% of the MBS group vs 49.3% in the non-MBS group ( P < 0.001). The proportion of patients with MBS increased from 1.6% (1998-2008) to 3.4% in the later years (2009-2019) ( P < 0.001). There were proportionately more unintentional overdoses in the MBS cohort (71% vs 52%, P < 0.001) with smaller median total APAP dose ingestion (6,500 mg vs 12,000 mg, P = 0.009). Although MBS patients had more severe encephalopathy at presentation, overall, 21-day and transplant-free survival between the groups were similar. DISCUSSION: ALF/ALI is more frequent in MBS patients than in the general population. APAP toxicity is the most common cause in MBS patients but not the only diagnosis observed. MBS may predispose to severe unintentional APAP liver injury at lower doses. Both MBS patients and providers should be aware regarding this potential risk of increased susceptibility to APAP hepatotoxicity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.